UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

European psychiatry, 2006-09, Vol.21 (6), p.367-378

2006

Volltextzugriff (PDF)

Error reductions over time in Virgil eCOA versus paper-based administrations in psychiatry trials

European neuropsychopharmacology, 2016-10, Vol.26, p.S470-S471

2016

Volltextzugriff (PDF)

Poster #176 NSA-16 REVISITED: IDENTIFYING LATENT FACTORS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

Schizophrenia research, 2012-04, Vol.136, p.S344-S344

2012

Volltextzugriff (PDF)

P.2.b.027 A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder (MDD) using central ratings

European neuropsychopharmacology, 2013-10, Vol.23, p.S334-S335

2013

Volltextzugriff (PDF)

P.1.i.009 Some urban legends of CNS clinical trial methodology: unsuccessful solutions to the problem of failed trials

European neuropsychopharmacology, 2012-10, Vol.22, p.S223-S224

2012

Volltextzugriff (PDF)

Poster #177 THE USE OF THE NSA-16 BY VIDEOCONFERENCING IN A CLINICAL TRIAL

Schizophrenia research, 2012-04, Vol.136, p.S344-S345

2012

Volltextzugriff (PDF)

P.8.b.004 Feasibility of centralised ratings for mental health safety screening in a dermatology trial

European neuropsychopharmacology, 2013-10, Vol.23, p.S621-S622

2013

Volltextzugriff (PDF)

P.3.a.010 The use of the 16 item Negative Symptom Assessment (NSA-16) by videoconferencing in a clinical trial

European neuropsychopharmacology, 2012-10, Vol.22, p.S309-S309

2012

Volltextzugriff (PDF)

1922 – The evaluation of negative symptoms by videoconferencing in a clinical trial

European psychiatry, 2013, Vol.28, p.1-1

2013

Volltextzugriff (PDF)

2210 – A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder using central ratings

European psychiatry, 2013, Vol.28, p.1-1

2013

Volltextzugriff (PDF)

P-640 - The power of expectation bias

European psychiatry, 2012, Vol.27, p.1-1

2012

Volltextzugriff (PDF)

P-641 - The importance of rigor in post-baseline assessments in cns clinical trials

European psychiatry, 2012, Vol.27, p.1-1

2012

Volltextzugriff (PDF)

1902 – Feasibility of centralized ratings for mental health safety screening in a non-psychiatric clinical trial

European psychiatry, 2013, Vol.28, p.1-1

2013

Volltextzugriff (PDF)

674 MAINTENANCE OF EFFECT OF DULOXETINE IN PATIENTS WITH CHRONIC LOW BACK PAIN

European journal of pain, 2009-09, Vol.13 (S1), p.S195-S195

2009

Volltextzugriff (PDF)

P.2.f.028 - Error reductions over time in Virgil eCOA versus paper-based administrations in psychiatry trials

European neuropsychopharmacology, 2016-10, Vol.26, p.S470-S471

2016

Volltextzugriff (PDF)

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

The Journal of Prevention of Alzheimer's Disease, 2020, Vol.7 (3), p.152-157

2020

Volltextzugriff (PDF)

P.4.a.006 A fixed dose study of the efficacy and safety of duloxetine for the treatment of generalised anxiety disorder

European neuropsychopharmacology, 2006, Vol.16, p.S451-S451

2006

Volltextzugriff (PDF)

P.1.040 Efficacy of duloxetine treatment: Analysis of pooled data from six placebo- and SSRI-controlled clinical trials

European neuropsychopharmacology, 2004-10, Vol.14, p.S190-S190

2004

Volltextzugriff (PDF)

Modulation of behavioral and insulin responses by contextual stimuli paired with food

Physiology & behavior, 1989-04, Vol.45 (4), p.845-851

1989

Volltextzugriff (PDF)

A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study

Journal of the neurological sciences, 2019-10, Vol.405, p.128-128

2019

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

Error reductions over time in Virgil eCOA versus paper-based administrations in psychiatry trials

Poster #176 NSA-16 REVISITED: IDENTIFYING LATENT FACTORS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

P.2.b.027 A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder (MDD) using central ratings

P.1.i.009 Some urban legends of CNS clinical trial methodology: unsuccessful solutions to the problem of failed trials

Poster #177 THE USE OF THE NSA-16 BY VIDEOCONFERENCING IN A CLINICAL TRIAL

P.8.b.004 Feasibility of centralised ratings for mental health safety screening in a dermatology trial

P.3.a.010 The use of the 16 item Negative Symptom Assessment (NSA-16) by videoconferencing in a clinical trial

1922 – The evaluation of negative symptoms by videoconferencing in a clinical trial

2210 – A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder using central ratings

P-640 - The power of expectation bias

P-641 - The importance of rigor in post-baseline assessments in cns clinical trials

1902 – Feasibility of centralized ratings for mental health safety screening in a non-psychiatric clinical trial

674 MAINTENANCE OF EFFECT OF DULOXETINE IN PATIENTS WITH CHRONIC LOW BACK PAIN

P.2.f.028 - Error reductions over time in Virgil eCOA versus paper-based administrations in psychiatry trials

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

P.4.a.006 A fixed dose study of the efficacy and safety of duloxetine for the treatment of generalised anxiety disorder

P.1.040 Efficacy of duloxetine treatment: Analysis of pooled data from six placebo- and SSRI-controlled clinical trials

Modulation of behavioral and insulin responses by contextual stimuli paired with food

A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study

Suchergebnisse filtern